Physician profile
Dat Q Tran
NPI 1124259072
$35,184.40
in general payments reported to CMS, 2019-2025
34 companies · $2,600 in 2025
The $2,600 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $1,634 · 2021: $8,999 · 2022: $7,208 · 2023: $6,876 · 2024: $6,978 · 2025: $2,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $5,793 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,650.00 |
| Food and Beverage | $5,792.65 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27,106.25 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,341.71 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $832.15 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $822.76 | 2020-2025 | Cuvitru, Eohilia, Takhzyro |
| Genzyme Corporation | $679.55 | 2019-2025 | |
| Optinose US, INC. | $509.99 | 2020-2024 | |
| Csl Behring | $431.34 | 2019-2025 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $396.43 | 2019-2025 | |
| Pfizer INC. | $332.52 | 2019-2024 | |
| Galderma Laboratories, L.P. | $302.99 | 2024-2025 | Nemluvio |
| Jubilant Hollisterstier LLC | $297.53 | 2023-2025 | |
| Kaleo, INC. | $255.59 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $253.35 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $225.52 | 2025 | Neffy |
| Genentech USA, INC. | $199.21 | 2019-2025 | Xolair |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $166.51 | 2021-2025 | Opzelura, Monjuvi |
| Lilly USA, LLC | $120.88 | 2025 | Ebglyss |
| Dexcom, INC. | $116.81 | 2024 | Dexcom G7 Gss (161) |
| Immunocore Limited | $99.70 | 2025 | Kimmtrak |
| Amgen INC. | $95.85 | 2022-2025 | Tezspire |
| Greer Laboratories, INC. | $94.99 | 2019-2024 | Oralair |
| Astellas Pharma US INC | $79.99 | 2022 | |
| Shire North American Group INC | $74.51 | 2019 | |
| Pharming Healthcare, INC. | $73.24 | 2025 | Ruconest |
| Octapharma USA, INC. | $66.82 | 2021-2022 | |
| Alk-Abello, INC | $57.53 | 2021-2023 | Grastek, Odactra |
| Organon LLC | $33.72 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $26.77 | 2021 | |
| Circassia INC. | $17.14 | 2019 | |
| Leo Pharma INC. | $16.83 | 2023 | Adbry |
| Cycle Pharmaceuticals INC | $15.98 | 2025 | Sajazir |
| Janssen Biotech, INC. | $15.85 | 2020 | |
| Phadia US INC. | $12.51 | 2022 | |
| Iovance Biotherapeutics, INC. | $11.88 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dat Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.